364 related articles for article (PubMed ID: 27650916)
61. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
Stål P
World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
[TBL] [Abstract][Full Text] [Related]
62. Nut consumption and the prevalence and severity of non-alcoholic fatty liver disease.
Semmler G; Bachmayer S; Wernly S; Wernly B; Niederseer D; Huber-Schönauer U; Stickel F; Aigner E; Datz C
PLoS One; 2020; 15(12):e0244514. PubMed ID: 33382757
[TBL] [Abstract][Full Text] [Related]
63. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.
Henson JB; Simon TG; Kaplan A; Osganian S; Masia R; Corey KE
Aliment Pharmacol Ther; 2020 Apr; 51(7):728-736. PubMed ID: 32043602
[TBL] [Abstract][Full Text] [Related]
64. The Association of leptin with severity of non-alcoholic fatty liver disease: A population-based study.
Rotundo L; Persaud A; Feurdean M; Ahlawat S; Kim HS
Clin Mol Hepatol; 2018 Dec; 24(4):392-401. PubMed ID: 30068065
[TBL] [Abstract][Full Text] [Related]
65. Complete alcohol abstinence increases the risk of NAFLD but not severity. A population analysis with transient elastography.
Xiao J; Ng CH; Chan KE; Tang ASP; Teh R; Ling AHZ; Yong JN; Lim WH; Tan DJH; Tan C; Win KM; Bwa AH; Chew NWS; Huang D; Dan YY; Noureddin M; Siddiqui MS; Sanyal A; Tamaki N; Muthiah M
Scand J Gastroenterol; 2023 Jan; 58(1):76-82. PubMed ID: 35944527
[TBL] [Abstract][Full Text] [Related]
66. Moderate to severe, but not mild, nonalcoholic fatty liver disease associated with increased risk of gallstone disease.
Lee YC; Wu JS; Yang YC; Chang CS; Lu FH; Chang CJ
Scand J Gastroenterol; 2014 Aug; 49(8):1001-6. PubMed ID: 24989169
[TBL] [Abstract][Full Text] [Related]
67. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients.
Leung JC; Loong TC; Wei JL; Wong GL; Chan AW; Choi PC; Shu SS; Chim AM; Chan HL; Wong VW
Hepatology; 2017 Jan; 65(1):54-64. PubMed ID: 27339817
[TBL] [Abstract][Full Text] [Related]
68. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.
Siddiqui MS; Patidar KR; Boyett S; Luketic VA; Puri P; Sanyal AJ
Liver Int; 2016 Apr; 36(4):572-9. PubMed ID: 26713759
[TBL] [Abstract][Full Text] [Related]
69. Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease.
Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
J Gastrointestin Liver Dis; 2015 Mar; 24(1):61-8. PubMed ID: 25822435
[TBL] [Abstract][Full Text] [Related]
70. Reduced lysosomal acid lipase activity - A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients.
Selvakumar PK; Kabbany MN; Lopez R; Tozzi G; Alisi A; Alkhouri N; Nobili V
Dig Liver Dis; 2016 Aug; 48(8):909-13. PubMed ID: 27198736
[TBL] [Abstract][Full Text] [Related]
71. Risk of severe illness of COVID-19 patients with NAFLD and increased NAFLD fibrosis scores.
Yao R; Zhu L; Wang J; Liu J; Xue R; Xue L; Liu L; Li C; Zhao H; Cheng J; Huang S; Li Y; Zhao XA; Zhu C; Li M; Huang R; Wu C
J Clin Lab Anal; 2021 Aug; 35(8):e23880. PubMed ID: 34213039
[TBL] [Abstract][Full Text] [Related]
72. The relationship between alcohol consumption and chronic kidney disease in patients with nonalcoholic fatty liver disease.
Zheng T; Wang X; Kamili K; Luo C; Hu Y; Wang D; Wang B; Gao P; Tian G
Scand J Gastroenterol; 2024 Apr; 59(4):480-488. PubMed ID: 38179969
[No Abstract] [Full Text] [Related]
73. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
Verma S; Jensen D; Hart J; Mohanty SR
Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
[TBL] [Abstract][Full Text] [Related]
74. Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness.
Sunbul M; Agirbasli M; Durmus E; Kivrak T; Akin H; Aydin Y; Ergelen R; Yilmaz Y
Atherosclerosis; 2014 Dec; 237(2):490-3. PubMed ID: 25463079
[TBL] [Abstract][Full Text] [Related]
75. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011).
Lee YH; Kim SU; Song K; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Han KH
Hepatology; 2016 Mar; 63(3):776-86. PubMed ID: 26638128
[TBL] [Abstract][Full Text] [Related]
76. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.
Le MH; Devaki P; Ha NB; Jun DW; Te HS; Cheung RC; Nguyen MH
PLoS One; 2017; 12(3):e0173499. PubMed ID: 28346543
[TBL] [Abstract][Full Text] [Related]
77. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease.
Alkayyali T; Qutranji L; Kaya E; Bakir A; Yilmaz Y
Acta Diabetol; 2020 May; 57(5):613-618. PubMed ID: 31897769
[TBL] [Abstract][Full Text] [Related]
78. Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study.
Chan WK; Ida NH; Cheah PL; Goh KL
J Dig Dis; 2014 Oct; 15(10):545-52. PubMed ID: 25060399
[TBL] [Abstract][Full Text] [Related]
79. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.
Ajmera V; Perito ER; Bass NM; Terrault NA; Yates KP; Gill R; Loomba R; Diehl AM; Aouizerat BE;
Hepatology; 2017 Jan; 65(1):65-77. PubMed ID: 27532276
[TBL] [Abstract][Full Text] [Related]
80. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
